乳腺癌Ki67染色的实验室间变异
30家欧洲病理实验室按各自常规流程对乳腺癌组织芯片进行Ki67染色,由一名观察者中心评估70例配对样本的Ki67标记指数。结果显示实验室间中位Ki67-LI(0.65%-33.0%,p<0.0001)及luminal A分类比例(17%-57%,p<0.0001)存在显著差异,结论认为将Ki67-LI用于治疗决策时需充分了解实验室特异性参考值。
要点
- 30家实验室中位Ki67-LI范围为0.65%-33.0%,差异显著(p<0.0001)。
- luminal A分类比例在各实验室间为17%-57%,差异显著(p<0.0001)。
- 按抗体分层或排除未参加外部质控的实验室后差异仍显著(p<0.0001)。
核心结论
- 30家常规病理实验室对乳腺癌组织Ki67染色存在显著变异,临床使用Ki67-LI做治疗决策时应充分了解实验室特异性参考值。
研究设计与样本
- 30家欧洲病理实验室按各自常规院内流程对同一乳腺癌组织芯片系列切片进行Ki67染色。
- 由一名观察者中心评估70例配对样本的Ki67标记指数(Ki67-LI),计数每例样本全部癌细胞。
主要发现
- 30家实验室中位Ki67-LI范围为0.65%-33.0%,差异显著(p<0.0001)。
- 将雌激素受体阳性癌按Ki67-LI低(<14%,luminal A)与高(≥14%,luminal B HER2阴性)二分后,各实验室luminal A分类比例范围为17%-57%,差异显著(p<0.0001)。
- 按使用同一抗体(MIB-1、SP6或30-9)的实验室分别分析,或排除既往未参加外部质量保证计划的实验室后,差异仍显著(p<0.0001)。
关键数值与推荐
- 中位Ki67-LI在30家实验室间为0.65%-33.0%(p<0.0001)。
- luminal A分类比例在30家实验室间为17%-57%(p<0.0001)。
- Ki67-LI二分阈值为<14%定义为luminal A,≥14%定义为luminal B HER2阴性。
临床怎么用
- 作者认为,将Ki67-LI用于治疗决策时应充分考虑实验室特异性参考值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postanalytic issues of Ki67 assessment in breast cancers like counting method standardisation and interrater bias have been subject of various studies, but little is known about analytic variability of Ki67 staining between pathology labs. Our aim was to study interlaboratory variability of Ki67 staining in breast cancer using tissue microarrays (TMAs) and central assessment to minimise preanalytic and postanalytic influences. METHODS: Thirty European pathology labs stained serial slides of a TMA set of breast cancer tissues with Ki67 according to their routine in-house protocol. The Ki67-labelling index (Ki67-LI) of 70 matched samples was centrally assessed by one observer who counted all cancer cells per sample. We then tested for differences between the labs in Ki67-LI medians by analysing variance on ranks and in proportions of tumours classified as luminal A after dichotomising oestrogen receptor-positive cancers into cancers showing low (<14%, luminal A) and high (≥14%, luminal B HER2 negative) Ki67-LI using Cochran's Q. RESULTS: Substantial differences between the 30 labs were indicated for median Ki67-LI (0.65%-33.0%, p < 0.0001) and proportion of cancers classified as luminal A (17%-57%, p < 0.0001). The differences remained significant when labs using the same antibody (MIB-1, SP6, or 30-9) were analysed separately or labs without prior participation in external quality assurance programs were excluded (p < 0.0001, respectively). CONCLUSION: Substantial variability in Ki67 staining of breast cancer tissue was found between 30 routine pathology labs. Clinical use of the Ki67-LI for therapeutic decisions should be considered only fully aware of lab-specific reference values.
引用
- Focke CM, Bürger H, van Diest PJ, et al. Interlaboratory variability of Ki67 staining in breast cancer. Eur J Cancer. 2017. PMID: 28829990. doi:10.1016/j.ejca.2017.07.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。